BACKGROUND: Neurotrophic factors (nerve growth factor [NGF], brain-derived neurotrophic factor [BDNF] and glial-derived neurotrophic factor [GDNF]) are growth factors implicated in the growth and differentiation of brain nerve cells. An involvement of these factors in the biology and progression of some specific tumours has been suggested. In accordance with the role of neurotrophic factors in tumour behaviour the aim of the present study was to investigate their expression in two childhood brain neoplasms, namely low-grade astrocytomas and ependymomas. MATERIALS AND METHODS: We investigated the NGF, BDNF, GDNF and NGF receptors (TrkA and p75) expression in the tumour tissues, cerebrospinal fluid (CSF) and plasma of ten children affected by low-grade astrocytomas and ependymomas. Control tissue samples (together with CSF and plasma samples) were obtained from patients who underwent surgery for cerebral vascular or epileptogenic lesions. RESULTS: The expression of NGF decreases both in tumour samples and in the CSF of affected children compared with controls. BDNF instead increases in CSF, while the expression of GDNF remains unchanged both in tissues and in CSF. No differences were found in neurotrophic factor plasma levels in patients or in controls. Gene expression of NGF and its high-affinity receptor (TrkA) are reduced in tumour tissues, whereas the number of cells immunopositive to the low-affinity NGF receptor (p75) is increased. CONCLUSION: Reduced expression of NGF and TrkA has been shown in low-grade astrocytomas and ependymomas. These findings may be related to the role of this neurotrophin in cell differentiation and apoptosis. The different expression of NGF, BDNF, and GDNF in low-grade astrocytomas and ependymomas suggests that a different degree of redundancy exists among members of the neurotrophic factor family and that their expression may be correlated with the biology and the behaviour of these tumours.
BACKGROUND: Neurotrophic factors (nerve growth factor [NGF], brain-derived neurotrophic factor [BDNF] and glial-derived neurotrophic factor [GDNF]) are growth factors implicated in the growth and differentiation of brain nerve cells. An involvement of these factors in the biology and progression of some specific tumours has been suggested. In accordance with the role of neurotrophic factors in tumour behaviour the aim of the present study was to investigate their expression in two childhood brain neoplasms, namely low-grade astrocytomas and ependymomas. MATERIALS AND METHODS: We investigated the NGF, BDNF, GDNF and NGF receptors (TrkA and p75) expression in the tumour tissues, cerebrospinal fluid (CSF) and plasma of ten children affected by low-grade astrocytomas and ependymomas. Control tissue samples (together with CSF and plasma samples) were obtained from patients who underwent surgery for cerebral vascular or epileptogenic lesions. RESULTS: The expression of NGF decreases both in tumour samples and in the CSF of affected children compared with controls. BDNF instead increases in CSF, while the expression of GDNF remains unchanged both in tissues and in CSF. No differences were found in neurotrophic factor plasma levels in patients or in controls. Gene expression of NGF and its high-affinity receptor (TrkA) are reduced in tumour tissues, whereas the number of cells immunopositive to the low-affinity NGF receptor (p75) is increased. CONCLUSION: Reduced expression of NGF and TrkA has been shown in low-grade astrocytomas and ependymomas. These findings may be related to the role of this neurotrophin in cell differentiation and apoptosis. The different expression of NGF, BDNF, and GDNF in low-grade astrocytomas and ependymomas suggests that a different degree of redundancy exists among members of the neurotrophic factor family and that their expression may be correlated with the biology and the behaviour of these tumours.
Authors: M A Grotzer; A J Janss; K Fung; J A Biegel; L N Sutton; L B Rorke; H Zhao; A Cnaan; P C Phillips; V M Lee; J Q Trojanowski Journal: J Clin Oncol Date: 2000-03 Impact factor: 44.544
Authors: A Nakagawara; M Arima-Nakagawara; N J Scavarda; C G Azar; A B Cantor; G M Brodeur Journal: N Engl J Med Date: 1993-03-25 Impact factor: 91.245
Authors: G L Colucci-D'Amato; A D'Alessio; D Califano; G Cali; C Rizzo; L Nitsch; G Santelli; V de Franciscis Journal: J Biol Chem Date: 2000-06-23 Impact factor: 5.157
Authors: Christian Hagel; András Treszl; Julia Fehlert; Jonas Harder; Franziska von Haxthausen; Meike Kern; André O von Bueren; Uwe Kordes Journal: J Neurooncol Date: 2013-01-31 Impact factor: 4.130
Authors: C Calatozzolo; A Salmaggi; B Pollo; F L Sciacca; M Lorenzetti; A Franzini; A Boiardi; G Broggi; C Marras Journal: Neurol Sci Date: 2008-01-04 Impact factor: 3.307
Authors: Antonio Ruggiero; Daniela Rizzo; Martina Catalano; Giorgio Attinà; Riccardo Riccardi Journal: Front Pharmacol Date: 2017-04-12 Impact factor: 5.810
Authors: Michel Le Van Quyen; Franck Bielle; Christophe Pellegrino; Johan Pallud; Pascale Varlet; Noemie Cresto; Michel Baulac; Charles Duyckaerts; Nazim Kourdougli; Geneviève Chazal; Bertrand Devaux; Claudio Rivera; Richard Miles; Laurent Capelle; Gilles Huberfeld Journal: Sci Transl Med Date: 2014-07-09 Impact factor: 17.956
Authors: Martha Assimakopoulou; Maria Kondyli; George Gatzounis; Theodore Maraziotis; John Varakis Journal: BMC Cancer Date: 2007-10-31 Impact factor: 4.430